TRX vs. AREC, C4XD, ETX, REDX, POLB, HEMO, SAR, ONC, SBTX, and OPTI
Should you be buying Tissue Regenix Group stock or one of its competitors? The main competitors of Tissue Regenix Group include Arecor Therapeutics (AREC), C4X Discovery (C4XD), e-therapeutics (ETX), Redx Pharma (REDX), Poolbeg Pharma (POLB), Hemogenyx Pharmaceuticals (HEMO), Sareum (SAR), Oncimmune (ONC), SkinBioTherapeutics (SBTX), and OptiBiotix Health (OPTI). These companies are all part of the "biotechnology" industry.
Arecor Therapeutics (LON:AREC) and Tissue Regenix Group (LON:TRX) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, earnings, valuation, media sentiment, analyst recommendations, dividends, risk, community ranking and institutional ownership.
In the previous week, Tissue Regenix Group had 1 more articles in the media than Arecor Therapeutics. MarketBeat recorded 1 mentions for Tissue Regenix Group and 0 mentions for Arecor Therapeutics. Tissue Regenix Group's average media sentiment score of 0.00 equaled Arecor Therapeutics'average media sentiment score.
Tissue Regenix Group received 162 more outperform votes than Arecor Therapeutics when rated by MarketBeat users.
Arecor Therapeutics has a beta of -0.22, suggesting that its share price is 122% less volatile than the S&P 500. Comparatively, Tissue Regenix Group has a beta of 1.48, suggesting that its share price is 48% more volatile than the S&P 500.
Tissue Regenix Group has higher revenue and earnings than Arecor Therapeutics. Tissue Regenix Group is trading at a lower price-to-earnings ratio than Arecor Therapeutics, indicating that it is currently the more affordable of the two stocks.
54.2% of Arecor Therapeutics shares are owned by institutional investors. Comparatively, 50.1% of Tissue Regenix Group shares are owned by institutional investors. 31.3% of Arecor Therapeutics shares are owned by company insiders. Comparatively, 48.1% of Tissue Regenix Group shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Tissue Regenix Group has a net margin of -5.81% compared to Tissue Regenix Group's net margin of -278.81%. Arecor Therapeutics' return on equity of -5.55% beat Tissue Regenix Group's return on equity.
Summary
Tissue Regenix Group beats Arecor Therapeutics on 10 of the 13 factors compared between the two stocks.
Get Tissue Regenix Group News Delivered to You Automatically
Sign up to receive the latest news and ratings for TRX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Tissue Regenix Group Competitors List
Related Companies and Tools
